Dyspnea in patients treated with P2Y12 receptor antagonists: insights from the GReek AntiPlatElet (GRAPE) registry

Abstract In ‘real life’ acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) and receiving contemporary antiplatelet treatment, data on dyspnea occurrence and impact on persistence with treatment are scarce. In a prospective, multicenter, cohort study, ACS patients undergoing PCI were recruited into the GReekAntiPlatElet (GRAPE) registry. During 1-year follow up, overall, 249/1989 (12.5%) patients reported dyspnea, more frequently at 1-month and decreasing thereafter. Multivariate analysis showed that ticagrelor administration (n = 738) at discharge was associated with the occurrence of dyspnea: Odds ratio 2.46 (95% confidence interval, CI, 1.87–3.25), p < 0.001. Older age, lower hematocrit, and prior bleeding event were also associated with dyspnea reports. Persistence, switching, and cessation rates were 68.3%, 20.9%, and 10.8% vs 76.7%, 12.5%, and 10.9% among patients reporting dyspnea compared with those who did not, p for trend = 0.002. In conclusion, in ACS patients undergoing PCI and treated with a P2Y12 receptor antagonist, dyspnea occurs commonly, particularly when ticagrelor is administered. Non-persistence with antiplatelet agents at discharge is more frequently observed among dyspnea-reporters.

[1]  Ioanna Xanthopoulou,et al.  Falta de persistencia con el tratamiento antiplaquetario contemporáneo al año en pacientes con síndrome coronario agudo sometidos a intervención coronaria percutánea , 2016 .

[2]  J. Goudevenos,et al.  One-year Non-persistence With Contemporary Antiplatelet Therapy in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention. , 2016, Revista espanola de cardiologia.

[3]  Marc P. Bonaca,et al.  Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. , 2016, JAMA cardiology.

[4]  J. Goudevenos,et al.  Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1‐year outcomes from the GReek AntiPlatElet (GRAPE) Registry , 2016, Journal of thrombosis and haemostasis : JTH.

[5]  G. Parodi,et al.  Dyspnoea management in acute coronary syndrome patients treated with ticagrelor , 2015, European heart journal. Acute cardiovascular care.

[6]  M. Effron,et al.  One-Year Post-Discharge Resource Utilization and Treatment Patterns of Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention and Treated with Ticagrelor or Prasugrel , 2015, American Journal of Cardiovascular Drugs.

[7]  H. Gurm,et al.  Contemporary Use of Ticagrelor in Interventional Practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium). , 2015, The American journal of cardiology.

[8]  S. Manzano-Fernández,et al.  Ticagrelor related dyspnea in patients with acute coronary syndromes: Incidence and implication on ticagrelor withdrawn. , 2015, International journal of cardiology.

[9]  Marc P. Bonaca,et al.  Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.

[10]  M. Keltai,et al.  Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial , 2015, Journal of the American Heart Association.

[11]  A. Vannacci,et al.  Ticagrelor-related dyspnea: an underestimated and poorly managed event? , 2015, International journal of cardiology.

[12]  P. Dehghani,et al.  Southern Saskatchewan Ticagrelor Registry experience , 2014, Patient preference and adherence.

[13]  I. Xanthopoulou,et al.  Ticagrelor vs prasugrel one-month maintenance therapy: Impact on platelet reactivity and bleeding events , 2014, Thrombosis and Haemostasis.

[14]  L. Maillard,et al.  Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients. , 2014, International journal of cardiology.

[15]  J. Sidaway,et al.  Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1 , 2014, Journal of cardiovascular pharmacology and therapeutics.

[16]  C. Stefanadis,et al.  Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE). , 2013, International journal of cardiology.

[17]  G. Brandrup-Wognsen,et al.  Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. , 2013, Journal of the American College of Cardiology.

[18]  E. Faioni,et al.  Why does ticagrelor induce dyspnea? , 2012, Thrombosis and Haemostasis.

[19]  C. Cannon,et al.  Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. , 2011, European heart journal.

[20]  C. Cannon,et al.  Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). , 2011, The American journal of cardiology.

[21]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[22]  P. Gurbel,et al.  Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. , 2010, Journal of the American College of Cardiology.

[23]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[24]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[25]  C. Cannon,et al.  Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. , 2007, Journal of the American College of Cardiology.

[26]  P. Sandset,et al.  Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. , 2006, European heart journal.

[27]  L. Wallentin,et al.  Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). , 2016, European heart journal. Cardiovascular pharmacotherapy.

[28]  C. Stefanadis,et al.  In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. , 2014, American heart journal.